Vanguard Global Advisers
SION

Vanguard Global Advisers’s Sionna Therapeutics SION Stock Holding History

Vanguard Global Advisers’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$345K Sell
7,852
-3,339
-30% -$134K ﹤0.01% 2268
2026
Q1 		$449K Buy
+11,191
New +$427K ﹤0.01% 2095

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Global Advisers's SION Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Sionna Therapeutics (SION) stake by 30% in Q2 2026, selling an estimated $134K and leaving 7,852 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #2268.

Vanguard Global Advisers first reported a position in SION in Q1 2026 and has held it in 2 quarters since. The position peaked at $449K in Q1 2026. 147 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Vanguard Global Advisers held 7,852 shares of Sionna Therapeutics worth $345K as of Q2 2026.
  • Vanguard Global Advisers sold 3,339 Sionna Therapeutics shares in Q2 2026, an estimated $134K.
  • Sionna Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2268 holding.
  • Vanguard Global Advisers first reported a position in Sionna Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Sionna Therapeutics position peaked at $449K in Q1 2026.
  • 147 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.